Efficacy Investigation of a chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio®) in the treatment of Otodectes cynotis in dogs

Abstract Background: Otoacariasis is a highly contagious, pruritic infestation of dogs caused by the ear mite Otodectes cynotis . Treatment with either moxidectin or sarolaner has been successful in dogs. Methods: In a dose confirmation study and a clinical field study, the efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ® ; Zoetis) against natural ear mite infestation was evaluated. In the dose confirmation study, efficacy was evaluated on Day 14 and 30 after a single treatment at a dose of 1.2 mg/kg sarolaner, 0.024 mg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt). In the field study, efficacy of the commercial dose of Simparica Trio was evaluated as parasitological cure rate after a single treatment and its non-inferiority to the control product (Advocate ® spot-on, 100 mg/mL (minimum 10mg/kg) imidacloprid + 25 mg/mL (minimum 2.5 mg/kg) moxidectin; Elanco Animal Health) was evaluated. If mites were still present on Day 30, a second treatment was provided, and efficacy was evaluated on Day 60. Results: In the dose confirmation study, otoscopy showed no mites in any of the Simparica Trio-treated dogs on Day 14 or Day 30, and a 100% efficacy ( P < 0.0001) was achieved against O. cynotis . In the field study, the parasitological cure rate in the Simparica Trio-treated dogs was 87.1% on Day 14 and 96.8% on Day 30 compared to 75.0% on Day 14 and 83.3% on Day 30 in Advocate spot-on-treated dogs. Three Simparica Trio-treated dogs were treated again on Day 30, resulting in a 100% efficacy on Day 60. The efficacy for Simparica Trio, as determined by parasitological cure rate, was non-inferior to Advocate spot-on solution on both Days 14 and 30. Conclusions: The results of the dose confirmation and clinical field study demonstrate the safety and high efficacy of Simparica Trio against natural infestations with O. cynotis in dogs.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-04
DOI
https://doi.org/10.21203/rs.3.rs-11387722/v1
Primary Topic
Dermatological diseases and infestations
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
preprint

Efficacy Investigation of a chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio®) in the treatment of Otodectes cynotis in dogs

Thomas Geurden, Giulia Venegoni, Anne Lloyd, Giulia Morganti et al.
Research Square
Dermatological diseases and infestations
preprint

Efficacy Investigation of a chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio®) in the treatment of Otodectes cynotis in dogs

Thomas Geurden, Giulia Venegoni, Anne Lloyd, Giulia Morganti, Fabrizia Veronesi, Lucas Taylor
preprint en

Abstract

Abstract Background: Otoacariasis is a highly contagious, pruritic infestation of dogs caused by the ear mite Otodectes cynotis . Treatment with either moxidectin or sarolaner has been successful in dogs. Methods: In a dose confirmation study and a clinical field study, the efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ® ; Zoetis) against natural ear mite infestation was evaluated. In the dose confirmation study, efficacy was evaluated on Day 14 and 30 after a single treatment at a dose of 1.2 mg/kg sarolaner, 0.024 mg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt). In the field study, efficacy of the commercial dose of Simparica Trio was evaluated as parasitological cure rate after a single treatment and its non-inferiority to the control product (Advocate ® spot-on, 100 mg/mL (minimum 10mg/kg) imidacloprid + 25 mg/mL (minimum 2.5 mg/kg) moxidectin; Elanco Animal Health) was evaluated. If mites were still present on Day 30, a second treatment was provided, and efficacy was evaluated on Day 60. Results: In the dose confirmation study, otoscopy showed no mites in any of the Simparica Trio-treated dogs on Day 14 or Day 30, and a 100% efficacy ( P < 0.0001) was achieved against O. cynotis . In the field study, the parasitological cure rate in the Simparica Trio-treated dogs was 87.1% on Day 14 and 96.8% on Day 30 compared to 75.0% on Day 14 and 83.3% on Day 30 in Advocate spot-on-treated dogs. Three Simparica Trio-treated dogs were treated again on Day 30, resulting in a 100% efficacy on Day 60. The efficacy for Simparica Trio, as determined by parasitological cure rate, was non-inferior to Advocate spot-on solution on both Days 14 and 30. Conclusions: The results of the dose confirmation and clinical field study demonstrate the safety and high efficacy of Simparica Trio against natural infestations with O. cynotis in dogs.

Research Square
University of Perugia (IT), Zoetis (United States) (US)
Dermatological diseases and infestations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon